Don't worry if you never heard of Dr. J. Joseph Kim. Most investors haven't-at least not yet. He's the CEO of an early-stage biotech firm that has developed a truly novel product for one of the nation's major medical markets -- vaccines. It's a $30 billion a year business in just the U.S. alone. The problem is that the vaccine technology we use today to prevent diseases like the flu, chicken pox and polio is hopelessly outdated because it still relies on the delivery of a portion of the actual virus to develop immunity. Not only that, but some of these agents are still grown in chicken eggs like they were back in the 1930s. And while they are still relatively safe, the vaccines themselves or their additives can still make people sick. But what if you could develop a whole new class of vaccines that were actually safe using a synthetic DNA? Better yet, what if you could vaccinate yourself against HIV, cervical cancer, leukemia, and hepatitis? The payoff would be tremendous. Now you know why I was so anxious to meet with Kim, the founder and CEO of Inovio Pharmaceuticals Inc. ( NYSE:INO ) last week. To continue reading, please click here...